Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635700 · ClinicalTrials.gov registry record · Phase 2
Ziprasidone in the Psychosis Prodrome
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00635700 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 51 participants.
The verdict
NCT00635700, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Interventions
- DRUG placebo
- DRUG ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635700
The ClinicalTrials.gov registry entry for NCT00635700 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00635700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00635700 about?
NCT00635700 is a clinical study titled "Ziprasidone in the Psychosis Prodrome". This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
What is the current status of trial NCT00635700?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2008-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00635700?
The interventions under investigation include: placebo (DRUG), ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00635700?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.